Center-Specific Neuropathology Procedures Survey Erin M. Pfeiffer 10/12/2002 NACC National Alzheimer’s Coordinating Center.

Slides:

Advertisements

Similar presentations

Endothelial Progenitor Cell (EPC) Core Laboratory Instructions Version 5.0 March 29, 2008 For questions regarding collection, processing, storage, or shipping.

Advertisements

The IndianaCTSI Biorepository is committed to serving the repository needs for CTSI investigators. The core will tailor specimen management to the needs.

Agenda: - Update on master tracers’ segmentation check - Update validation vs pathology - PMT application submission of “Study on the validation of VSRAD”

Frontotemporal Dementia

Introduction to Pathology. What is pathology Pathology is the scientific study of disease. In its broadest sense, it is the study of how the organs and.

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.

CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.

MCB 135K: Discussion March 2, General Info Mid-Term I: –Avg 87 –Std. Deviation 10 –Re-grades by next Wednesday Include a cover sheet that addresses.

NACC National Alzheimer’s Coordinating Center Neuropathology Core Leaders Meeting NACC Update, June 2004 Cleveland W. A. Kukull, PhD.

NACC National Alzheimer’s Coordinating Center NACC Update ADC Director’s Meeting October 2003.

Clinical Task Force Report ADC Directors’ Meeting April 24, 2004, San Francisco l Review of plans from 10/18/03 Directors’ Meeting l UDS survey results.

CN-1 Neuropathology of Parkinson’s Disease Dementia James B. Leverenz, MD Associate Professor Neurology and Psychiatry and Behavioral Sciences University.

Dementia with Lewy Bodies

A 67-year-old male with behavioral and language problems

Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Presented by: Beau Ances,

Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.

SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.

FTD Family Members Study & Post Mortem Study Alyson Negreira MGH Frontotemporal Disorders Unit.

Mesothelioma Collections September 2010 through September 2011.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

Procedures Manual, Control Series, & Phenotype Committee Update Stephanie Doan, MPH NIA AD Genetics Initiative Co-Coordinator Columbia University.

Biobanks of Cerice Center for Gene Expression Research in Cancer Epidemiology Eiliv Lund, UiTø.

CU-1 Summary of Neuropathological and Clinical Features of PDD Clive Ballard, MD Professor of Age Related Diseases Institute of Psychiatry King’s College.

Laboratory Careers Packet #4. Introduction Individuals working in this field have various tasks, duties, interests and abilities. Laboratory personnel.

Diagnostic Slide Session Mark Samols 1, Kari-Elise Codispoti 1, Marc Rosenblum 2, Barbara Crain 1 1 Johns Hopkins Hospital, Baltimore MD 2 Memorial.

Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.

Peripheral and Central Nervous System Drugs Advisory Committee Meeting - March 14, Issues Related to the Development of Drugs for the Treatment.

Assessment and Diagnosis of Dementia Dr Alison Haddow.

Introduction to Pathology

High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.

NCRAD Update Tatiana Foroud, Ph.D. Indiana University.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Epilepsy Tissue Bank Institute of Neurology Jan 2013.

UCL Institute of Neurology Queen Square Brain Bank Department of Molecular Neuroscience The Queen Square Brain Bank Tamas Revesz Professor of Neuropathology.

Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.

BACKGROUND Screening for subclinical TDP43 neuropathology in autoimmune conditions: a pilot study Natasha Clarke, Nidhi Sofat, Lena Assi and Peter GarrardContact:

Retention period(s) of samples/data Many jurisdictions, as well as hospitals and institutions, mandate retention periods for medical or research-related.

Applications of Nanotechnology in Alzheimer’s Disease BioE 494 – Atomic and Molecular Nanotechnology Fall 2007 Deivya Bansal.

Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Absence of β-Amyloid Deposits After Immunization in.

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

Copyright © 1999 American Medical Association. All rights reserved.

Tissue Collection & Banking Facility

DOI: /j.neurobiolaging

Brain Tumour Bank at Institute of Neurology

Copyright © 2004 American Medical Association. All rights reserved.

Dementia: from molecules to minds

The Carroll A. Campbell, Jr. Neuropathology Laboratory (Brain Bank)

Frontotemporal dementia syndromes are united by underlying frontotemporal lobar degeneration pathology, which can be divided according to the presence.

Table 2. Data Sharing for (Reporting Period)

65 year-old female with Alzheimer’s disease

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

John F. Crary, MD-PhD Associate Professor

Mark S. Forman, Virginia M-Y. Lee, John Q. Trojanowski Neuron

Volume 15, Issue 13, Pages (December 2016)

Figure 3 Genetic pleiotropy in ALS

A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis Caitlin S. Latimer, Carol A. Shively,

Figure 2 Pathologic diagnosis of CAA-related vascular inflammation Hematoxylin & eosin staining (A) revealed focal intramural inflammation including lymphocytes,

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β.

S.P. Leibo, Ph.D., Thomas B. Pool, Ph.D. Fertility and Sterility

SYNOPSIS OF THE PROTOCOL

Postmortem Neurological Diagnosis A Postmortem Neurological Diagnosis or Brain-Only Autopsy, is the only definitive answer for families or researchers.

Molecular pathology of allergic disease

Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease W. Robert Bell, Yang An,

A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis Caitlin S. Latimer, Carol A. Shively,

TOMA does not affect NFTs in posterior hypothalamus or cortex.

UAB Tissue Biorepository

Presentation transcript:

Center-Specific Neuropathology Procedures Survey Erin M. Pfeiffer 10/12/2002 NACC National Alzheimer’s Coordinating Center

NACC Center-Specific Neuropathology Survey Dr. Cochran, Dr. Dickson, Dr. Ghetti Special Thanks – Dr. Jim Leverenz 10-page detailed survey 90.6 % response rate (29/32 surveys) Complete answers & thoughtful comments

NACC Survey Form

NACC

NACC

NACC

NACC General Questions: # NP-related data elements maintained in each Center’s Database # Variables StoredCountPercent % % % % > % Frequency Missing = 1

NACC General Questions (cont’d) > 90% maintaining data on:  AD pathological dx  Plaques/tangles  PD pathological dx  Lewy bodies  Infarcts ~ 46% maintain genetic data ~ 62% collect circumstance of death (Including Centers who collect for some/not all subjects)

NACC Specimen and Tissue Preparation: Postmortem Interval Postmortem Interval (hrs) # of Centers

NACC Specimen and Tissue Preparation: Specimens Collected from Autopsy Percent of Centers Collecting Samples Specimen TypeFixedParaffinFrozenNone Hippocampus86 %100 %93 %-- Temporal Cortex86 %100 %90 % 3 % Pituitary Gland12 %28 %14 %52 % PNT* 7 % 3 %93 % * PNT = Peripheral Nervous Tissue

NACC Specimen and Tissue Preparation: Cryoprotection 40% store fixed tissue in cryoprotective solution Average time tissue fixed prior to transfer to cryoprotective solution = 2 days Cryoprotective solutions include: – 16% sucrose – 20% glycerol, 2% DMSO – Isopentane Liquid Nitrogen – Sucrose/ethylene glycol in phosphate buffer

NACC Specimen and Tissue Preparation: Biological Specimen Banking Biological SpecimenCountPercent DNA1763 % Serum1348 % Lymphocytes: Buffy Coat 830 % Lymphocytes: Lymphoblastoid ICL* 1 4 % Antemortem CSF 519 % * ICL = Immortalized Cell Lines Frequency Missing = 2

NACC Stains for identifying beta-amyloid pathology – 69 % Silver Stain (e.g. Bielschowsky, Bodian, Campbell-Switzer, Microwave King, Gallyas) – 35 % Thioflavin-S – 24 % Congo Red – 72 % Aß immunostain (e.g. GFAP, Novocastra, DAKO monoclonal mouse) Histopathology: Stains

NACC Stains for identifying neurofibrillary pathology – 76 % Silver Stain (e.g. Bielschowsky, Modified-Biel, Bodian, Microwave King, Gallyas) – 36 % Thioflavin-S – 83 % Tau immunostain (e.g. AT8, PHF-1, ALZ-50, Tau-2) Histopathology: Stains

NACC Neuropathology: Criteria AD PathologyCountPercent NIA/Reagan Institute2586 % CERAD2276 % ADRDA/Khachaturian 621 % Tierney-- Other * 517 % * Washington U modified Koch (1985), In house semi-quantitative methods, etc

NACC Neuropathology: Criteria FTD PathologyCountPercent Lund and Manchester* 932 % Work Group on FTD & PiD**1968 % Other 414 % * Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J of Neurology, Neurosurgery, and Neuropsychiatry 1994: **McKhann GM et al. Clinical and Pathological Diagnosis of Frontotemporal Dementia: report of the work group on frontotemporal dementia and Pick’s disease. Arch of Neurol 2001: Frequency Missing = 1

NACC Percentage of Centers that perform: – Immunoassays = 40% – In situ hybridization = 14% – Image analysis = 36% – Stereology = 25% – Microarray analysis = 32% Additional Procedures: Performed on NP core tissue

NACC Summary / Plans for NP Survey Data Detailed summary of NP procedures & specific specimens available at each ADC Dataset created - After NYC, contact a few ADCs for brief clarifications Survey results will be available via NACC’s website Data will be integrated into overall database (i.e. linked to MDS, Neuropathology data, other Centers data) Thanks again!

NACC